"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT05127122","Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS","EXIT-ARDS","Not yet recruiting","No Results Available","ARDS, Human","Drug: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Other: Saline","The incidence of serious adverse events.|Number to patients with All-Cause Mortality at 28 days|Ventilator-free days at 28days|Change in partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio from pre-infusion baseline(Day 0)to Day 7.PaO2 may be calculated from arterial blood gas (ABG)or imputed from the SpO2daily.","Direct Biologics, LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DB-EF-EXITARDS-0003","January 2023","January 2023","January 2023","November 19, 2021",,"September 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05127122"
2,"NCT05125562","Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19: A Phase II Clinical Trial",,"Not yet recruiting","No Results Available","COVID-19","Drug: ExoFlo","Change in SARS-CoV-2 log viral load from baseline to Day=7|Change in viral load area under the curve (AUC) from baseline to Day=29|Proportion of patients showing symptom improvement or resolution Day=7, 11, 15|- Proportion of patients who required COVID-19 related hospitalization or Emergency Department Visit by Day 29","Direct Biologics, LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DB-EF-EMOTECOVID-0006","December 7, 2022","March 7, 2023","March 7, 2023","November 18, 2021",,"August 25, 2022","Direct Biologics, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05125562"
3,"NCT05215288","Intermediate Size Expanded Access for the Use of ExoFlo in the Treatment of Abdominal Solid Organ Transplant Patients Who Are at Risk of Worsening Allograft Function With Conventional Immunosuppressive Therapy Alone",,"Not yet recruiting","No Results Available","Solid Organ Transplant Rejection|Organ Rejection Transplants|Organ Rejection","Biological: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment","Number of participants with adverse/serious adverse events","Direct Biologics, LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DB-EF-TRANSPLANT-0002","October 2022","October 2022","December 2022","January 31, 2022",,"September 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05215288"
4,"NCT05130983","A Phase I Study of ExoFlo, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Crohn's Disease",,"Not yet recruiting","No Results Available","Crohn Disease|IBD - Irritable Bowel Disease","Drug: Bone Marrow MSC Derived Extracellular Vesicle Isolate","• To evaluate the feasibility of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the safety of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in inducing clinical remission in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in inducing clinical response in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in improving disease-specific health-related quality of life.|• To evaluate the pharmacokinetics and pharmacodynamics of ExoFlo therapy, including changes in C-reactive protein (CRP), fecal calprotectin, fecal lactoferrin, and other pharmacodynamic biomarkers.","Direct Biologics, LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DB-EF-CROHNS-0004","September 1, 2022","January 1, 2024","March 1, 2024","November 23, 2021",,"September 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05130983"
5,"NCT05176366","Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis",,"Not yet recruiting","No Results Available","Ulcerative Colitis","Drug: ExoFlo","Number of subjects who tolerate intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of adverse events in subjects who received intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improvement with intravenous ExoFlo in inducing clinical remission in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improvement with intravenous ExoFlo in inducing clinical response in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improving disease-specific health-related quality of life after receiving intravenous ExoFlo.|Measurement of subject's C-reactive protein (CRP)|Measurement of subject fecal calprotectin|Measurement of subject fecal lactoferrin","Direct Biologics, LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DB-EF-ULCERATIVE-0004","December 1, 2022","January 1, 2024","March 1, 2024","January 4, 2022",,"September 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05176366"
6,"NCT05354141","Bone Marrow Mesenchymal Stem Cell Derived EVs for COVID-19 Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS): A Phase III Clinical Trial",,"Recruiting","No Results Available","COVID-19 Acute Respiratory Distress Syndrome","Drug: EXOFLO","The primary efficacy endpoint is overall 60-day mortality (due to any cause).","Direct Biologics, LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DB-EF-PHASEIII-0001","July 1, 2022","April 3, 2023","July 3, 2023","April 29, 2022",,"August 30, 2022","PRX Research, Mesquite, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05354141"
7,"NCT05116761","ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome",,"Not yet recruiting","No Results Available","Covid19|Postviral Syndrome|Dyspnea","Biological: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Other: Saline","Increased distance on Six Minute Walk Test (6MWT)|Incidence of Serious Adverse Events (SAEs)|EuroQol-5D (EQ-5D)|Medical Research Council (MRC) Dyspnea Scale","Direct Biologics, LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DB-EF-POSTCOVID-0002","February 2023","February 2023","February 2023","November 11, 2021",,"September 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05116761"
8,"NCT04493242","Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS","EXIT-COVID19","Completed","No Results Available","Covid19|ARDS|Pneumonia, Viral","Biological: DB-001|Other: Intravenous normal saline","7 Day Change in Partial Pressure of Arterial Oxygen to Fraction of Inspired Oxygen Ratio|Time to Recovery|Incidence of Serious Adverse Events (SAE)|Number of Patients with All-cause Mortality","Direct Biologics, LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DB-EF-PHASEII-001","September 24, 2020","May 1, 2021","May 22, 2021","July 30, 2020",,"January 14, 2022","Helen Keller Hospital, Sheffield, Alabama, United States|St. Joseph Hospital Heritage, Fullerton, California, United States|Donald Guthrie Foundation/ Robert Packer Hospital, Sayre, Pennsylvania, United States|Covenant Health, Lubbock, Texas, United States|PRX Research, Mesquite, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04493242"
